PGIM Jennison Health Sciences’ deep domain expertise and distinctive approach make for an attractive healthcare offering.
PGIM Jennison Health Sciences R PJHRX
- NAV / 1-Day Return 35.27 / −0.82 %
- Total Assets 1.7 Bil
-
Adj. Expense Ratio
1.480%
- Expense Ratio 1.480%
- Distribution Fee Level Low
- Share Class Type Retirement, Small
- Category Health
- Investment Style Large Growth
- Min. Initial Investment —
- Status Open
- TTM Yield —
- Turnover 64%
USD | NAV as of Apr 18, 2024 | 1-Day Return as of Apr 18, 2024, 10:21 PM GMT+0
Morningstar’s Analysis PJHRX
Will PJHRX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 50.5
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Eli Lilly and Co | 11.61 | 214.5 Mil | Healthcare |
Merck & Co Inc | 7.52 | 138.9 Mil | Healthcare |
AbbVie Inc | 6.61 | 122.1 Mil | Healthcare |
UnitedHealth Group Inc | 4.35 | 80.3 Mil | Healthcare |
Vertex Pharmaceuticals Inc | 4.21 | 77.8 Mil | Healthcare |
Apellis Pharmaceuticals Inc | 3.67 | 67.8 Mil | Healthcare |
The Cigna Group | 3.45 | 63.7 Mil | Healthcare |
Becton Dickinson & Co | 3.15 | 58.2 Mil | Healthcare |
Boston Scientific Corp | 3.01 | 55.7 Mil | Healthcare |
Novo Nordisk A/S ADR | 2.92 | 53.9 Mil | Healthcare |